Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 13/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 9/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 8/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.38 |
| ▸ | GPR183 | P32249 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL470613 | 0.86 | GPR119 (0.49) | DPP4DPP8DPP7DPP9GPR119 | |
| SCHEMBL470574 | 0.82 | GPR119 (0.45) | GPR119GPR183KCNH2 | |
| SCHEMBL12064990 | 0.80 | DPP4 (0.42) | DPP4DPP8DPP7DPP9GPR119 | |
| SCHEMBL470604 | 0.79 | GPR119 (0.49) | DPP4DPP8DPP9GPR119GPR183 | |
| SCHEMBL121162 | 0.79 | GPR119 (0.42) | DPP4DPP8DPP7DPP9GPR119 | |
| SCHEMBL12064609 | 0.79 | GPR119 (0.43) | DPP4DPP8DPP7DPP9GPR119 | |
| SCHEMBL12064995 | 0.79 | GPR119 (0.43) | DPP4DPP8DPP7DPP9GPR119 | |
| SCHEMBL470648 | 0.78 | GPR119 (0.49) | DPP4GPR119GPR183KCNH2MCHR1 | |
| SCHEMBL12064799 | 0.78 | GPR119 (0.42) | DPP4DPP8DPP7DPP9GPR119 | |
| SCHEMBL470621 | 0.77 | GPR119 (0.50) | DPP4GPR119GPR183KCNH2MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011147951-A1 | CYCLOAMINO DERIVATIVES AS GPR119 ANTAGONISTS | PROSIDION LIMITED (GB) | 2011-12-01 | — | — | WO | disclosed |